Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Capdevila

Showing results (131-140 of 136) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 136 results.
Nature Communications|May 23, 2023
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung originJ Capdevila, J Hernando, A Teule, et al.
Medrxiv : the Preprint Server for Health Sciences|December 3, 2020
Optimal symptom combinations to aid COVID-19 case identification: analysis from a community-based, prospective, observational cohortM Antonelli, J Capdevila, A Chaudhari, et al.
The Journal of Infection|February 16, 2021
Optimal symptom combinations to aid COVID-19 case identification: Analysis from a community-based, prospective, observational cohortM Antonelli, J Capdevila, A Chaudhari, et al.
ESMO Open|March 5, 2023
The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trialE A Dijkstra, W H Zwart, P J Nilsson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2010
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)R Garcia-Carbonero, J Capdevila, G Crespo-Herrero, et al.
ESMO Open|December 3, 2025
Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trialJ Capdevila, S Tafuto, M Krogh, et al.
Pageof 14

Showing results (131-140 of 136) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 136 results.
Nature Communications|May 23, 2023
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung originJ Capdevila, J Hernando, A Teule, et al.
Medrxiv : the Preprint Server for Health Sciences|December 3, 2020
Optimal symptom combinations to aid COVID-19 case identification: analysis from a community-based, prospective, observational cohortM Antonelli, J Capdevila, A Chaudhari, et al.
The Journal of Infection|February 16, 2021
Optimal symptom combinations to aid COVID-19 case identification: Analysis from a community-based, prospective, observational cohortM Antonelli, J Capdevila, A Chaudhari, et al.
ESMO Open|March 5, 2023
The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trialE A Dijkstra, W H Zwart, P J Nilsson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2010
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)R Garcia-Carbonero, J Capdevila, G Crespo-Herrero, et al.
ESMO Open|December 3, 2025
Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trialJ Capdevila, S Tafuto, M Krogh, et al.
Pageof 14